OBJECTIVES: Adalimumab and etanercept are patient self-administered biologic agents used in rheumatoid arthritis (RA) . Prescription refill gap analyses may be conducted to understand patient refill behavior as a proxy for compliance. The objective of this study was to evaluate gaps between prescription refills of adalimumab or etanercept across multiple databases and compare results of different methodologies. METHODS: Data were obtained from three retrospective claims databases (HealthCore Integrated Research Database-HIRD [adalimumab or etanercept initiation 07/2004 -10/2008 , MarketScan Commercial and Medicare Supplemental Claims databases [01/2003 -06/2008 , and Wolters Kluwer Pharma Solutions-WKPS database [01/2004-12/2008] ). Inclusion criteria: Ն18 years old, Ն2 RA diagnosis codes (ICD-9 code 714.xx), no biologic therapy 6 or 12 months prior to current therapy, one year of treatment persistence (HIRD and MarketScan only), and no selected inflammatory conditions. Mean gaps (days) in refills were calculated among all RA patients in MarketScan and WKPS, and calculated among only those patients with Ն1 day of gap in HIRD. Analyses included the first 15 refill periods. RESULTS: Data from 15,818 adalimumab and 25,175 etanercept patients were analyzed. Mean adalimumab gaps spanned 1.3 to 8.4 and 6.8 to 11.4 days in MarketScan and WKPS, respectively. Mean adalimumab gaps spanned 17.2 to 33.4 days in HIRD when calculated among only those patients with Ն1 day of gap in refilling. Mean etanercept gaps spanned 1.3 to 10.9, 6.6 to 14.2, and 16.3 to 37.4 days for MarketScan, WKPS, and HIRD, respectively. CONCLUSIONS: Results across multiple databases substantiate that refill gaps exist among adalimumab and etanercept users during each refill period. The specific methodology for calculating refill gaps should be considered. The extent of delayed refills may be underestimated when calculated across an entire population, instead of only among those with evidence of a gap. Further research is needed examining clinical and economic consequences associated with therapy gaps. Borah B Mayo Clinic, Rochester, MN, USA OBJECTIVES: Medication adherence has been linked to better health outcomes. Therefore, a comprehensive understanding of the predictors of adherence is essential for formulating adherence-improving strategies. Existing methods have not considered evaluation of heterogeneous impacts of predictors at different parts (quantiles) of the adherence distribution as defined by medication possession ratio. Using the novel econometric framework of unconditional quantile regression (UQR), this study assesses the heterogeneity of impacts of adherence predictors for an Alzheimer's disease (AD) population. METHODS: This retrospective claims analysis identified AD patients from a large US health plan that initiated oral AD therapy (rivastigmine, donepezil, galantamine, or memantine) between 1/1/2006 and 12/31/2007. Baseline characteristics were assessed during the 6-month pre-index period; medication adherence was assessed during the 1-year post-index period. UQR was estimated at 10 th , 20 th , . . ., 90 th quantiles. Predictors of adherence identified from the data included age, gender, indicator of mental health insurance coverage, region, commercial vs. Medicare insurance, log cost, comorbidity, and formulary tier for the AD medication. RESULTS: Baseline medication count was positively associated with adherence (pϽ0.05) in the upper half of the adherence distribution. Having mental health coverage is negatively associated with adherence in all but the 10 th and 20 th quantiles but the impact was substantially higher in the first half of the adherence distribution. Baseline (log) cost was positively associated with adherence in the 40 th and upper quantiles of the adherence distribution. For patients in the 80 th and 90 th quantiles, the number of baseline office visits predicted lower adherence. Compared to patients from the East, patients from the South were less likely to be adherent in the 60 th and 70 th quantiles. CONCLUSIONS: The study results highlight the heterogeneity of impacts of various adherence predictors -a predictor may be statistically significant only in specific quantiles of the adherence distribution, and the impacts may vary substantially between quantiles.
MC2 ASSESSING PREDICTORS OF MEDICATION ADHERENCE IN UNCONDITIONAL QUANTILE REGRESSION FRAMEWORK

MC3 IMPACT OF MULTIPLE MEDICATION COMPLIANCE ON CARDIOVASCULAR OUTCOMES IN PATIENTS WITH TYPE II DIABETES AND COMORBID HYPERTENSION CONTROLLING FOR ENDOGENEITY BIAS
An JJ, Nichol MB University of Southern California, Los Angeles, CA, USA OBJECTIVES: To investigate the impact of multiple medication compliance on the occurrence of cardiovascular disease (CVD) outcomes using instrumental variables (IV) to control for endogeneity bias. METHODS: We identified individuals who newly start oral diabetes or hypertension medication therapy between July 2006 and June 2007 with the pre-existing comorbid hypertension or diabetes prescription history during 6 months of pre-index period using administrative claims from a managed care organization in southern California (Nϭ1565). Multiple medication compliance was defined as a proportion of days covered for both diabetes and hypertension medications during three years of follow-up. Cardiovascular outcomes included myocardial infarction, stroke, and peripheral vascular disease. Instrumental variables estimation using physician related variables including a dummy for the same prescribers for both medications, the percentage of follow-up visit per physician, and the percentage of statin prescription per physician was implemented. Parameter estimates were compared using probit and IV-probit models. RESULTS: Mean compliances were 0.636 (Ϯ0.008) for diabetes medications, 0.686 (Ϯ0.008) for hypertension medications, and 0.527 (Ϯ0.008) for both medications. After adjusting for age, gender, baseline clinical measures (Hemoglobin A1C, blood pressure, and lipid), pre-existing condition (either diabetes or hypertension), and Elixhauser-comorbidity, adherence to both medications was not significantly associated with decreased CVD rate (Ϫ0.070Ϯ0.118, pϭ0.554) based on probit model. After controlling for endogeneity, however, the impact of multiple medication adherence became statistically significant using IV-probit model A8 V A L U E I N H E A L T H 1 4 ( 2 0 1 1 ) A 1 -A 2 1 4 (Ϫ2.270Ϯ0.345, pϽ0.0001). IVs satisfied identification conditions individually and as a group. The increasing multiple medication compliance from 50% to 80% was associated with the reduction of the average probability of predicted CVD occurrence from Ϫ0.46 (Ϯ0.091, pϽ0.0001) to Ϫ1.14 (Ϯ0.042, pϽ0.0001) at the mean level of covariates. CONCLUSIONS: After controlling for endogeneity bias, compliance with multiple medications was significantly associated with a decrease in the CVD event rate with type II diabetes and comorbid hypertension. were hospitalized for an acute MI between January 1 and June 30 of 2006, were identified using a validated algorithm, requiring a hospitalization episode Ն3 and Յ180 days with an ICD-9-CM of 410.x1 as primary or secondary diagnosis. Post-MI patients with an ACEI/ARB prescription within 90 days of discharge were followed to study patterns of discontinuation until December 31, 2007. Time to discontinuation was defined as the days from initiation of therapy to a therapy gap of Ͼ90 days. Survival curves were constructed using the Kaplan-Meier technique, and potential predictors of therapy discontinuation, including demographic characteristics, comorbidities and concomitant medications were estimated using Cox proportional hazards regression. RESULTS: Of the 1,949 subjects in the cohort, 66.1% were females, 82.9% were Caucasian with a mean age of 78.6 (Ϯ8.2) years. Approximately, 20% of the patients discontinued therapy within six months and 45% discontinued within a year. Caucasians were less likely to discontinue therapy as compared to blacks (HRϭ0.774; [0.638-0.939]; pϭ0.0094). Among the comorbid conditions, dyslipidemia (HRϭ0.734; [0.612-0.880]; pϭ0.0008), cerebrovascular disease (HRϭ1.124; [0.986-1.281]; pϭ0.0806) and COPD (HRϭ1.154; [1.013-1.316]; pϭ0.0319) were significant predictors of time to discontinuation. Patients on concomitant beta-blocker (HRϭ0.771; [0.627-0.949]; pϭ0.0141) and statin (HRϭ0.857; [0.736-0.999]; pϭ0.0491) therapy were less likely to discontinue ACEI/ARB therapy. CONCLUSIONS: Many patients initiating ACEI/ARB treatment following MI fail to consistently remain on therapy as is evident by the high rates of discontinuation within a year. Several factors including race and comorbidities are potential predictors of this behavior.
PODIUM SESSION III: RESEARCH ON METHODS: ECONOMIC EVALUATIONS
EE1 SYSTEMATIC REVIEW OF GUIDELINES FOR HEALTH ECONOMIC EVALUATIONS
Melnyk P, Wagner M, Dourdin N, Rindress D BioMedCom Consultants Inc., Dorval, QC, Canada OBJECTIVES: Numerous guidelines on conduct and reporting of health economic (HE) evaluations have been developed over several decades differing somewhat in their objectives, scope and specific recommendations. We systematically reviewed all accessible HE guidelines to identify commonalities and differences with respect to type and content of recommendations. METHODS: A systematic search of PubMed/Medline, the Centre for Reviews and Dissemination, the EQUATOR network, and websites of health technology assessment agencies and health care coverage decisionmaking bodies comprehensively identified publicly accessible HE guidelines. These were categorized as jurisdictional mandatory, jurisdictional nonmandatory or general guidelines. Data was extracted into a template devised to capture 30 fields of content. Both qualitative and quantitative analyses were performed. RESULTS: Seventy-four HE guidelines were obtained: 23 jurisdictional mandatory, 11 jurisdictional non-mandatory and 40 general. The most common topics addressed by guidelines were: sensitivity analysis (by 91%), data identification (89%), perspective (84%), choice of health outcomes (82%), assumptions (78%), valuation of resources (77%), types of costs (76%)/resources to include (74%), comparators (74%) and modeling (74%). Compared to jurisdictional guidelines, general guidelines focused on a narrower range of topics (e.g., modeling) and were less prescriptive. Although there was a level of agreement on many issues, areas of divergence were identified: study perspective (emphasis on society: 32% of guidelines; health care payer: 19%), unrelated costs in life-years gained (inclusion in base-case or sensitivity analysis recommended by 8%, exclusion by 7%), methods to value productivity losses (friction cost approach: 12%; human capital approach: 15%; other: 3%), and recommended type of sensitivity analysis (probabilistic: 28%; deterministic sufficient: 28%). CONCLUSIONS: Available guidelines for HE evaluations are diverse and cover a broad range of methodological and reporting issues. Except for specific jurisdictional needs and a few controversial issues, however, there appears to be convergence of HE guidance over time and stability of basic content. 
EE2
VALIDATION OF THE UPDATED CHARLSON COMORBIDITY INDEX (CCI) TO PREDICT HEALTH CARE UTILIZATION FOR DIABETIC PATIENTS USING ADMINISTRATIVE DATA
OBJECTIVES:
To validate the recently updated Charlson Comorbidity Index (CCI) for the prediction of future healthcare utilization for diabetic patients. METHODS: Administrative claims data were obtained for diabetic patients enrolled continuously for three years in the Department of Defense TRICARE program for retrospective analysis. The updated and the original CCI scores were calculated using baseline year data. Linear regression models were used to estimate log-transformed healthcare expenditures (COST) for one-and two-year post-index periods. Zeroinflated negative binomial regression models were used to estimate the number of hospitalizations (HOS) and the number of emergency department visits (ED) for one-and two-year post-index periods. The outcome variables were then dichotomized (above or below the 90 th percentile of COST; Ն 1 HOS or none; Ն 1 ED or none) and estimated using logistic regression models. Adjusted R ® , Akaike information criteria (AIC), and c statistics were assessed to compare the two CCI versions. RESULTS: A total of 8,704 patients were included in the study. The study population had a mean age of 51.0 years (SD: 10.5), and 46.3 percent were male. In the linear regression models, the updated CCI explained more variance than the original CCI in one-year COST (adjusted R ® ϭ 13.0% vs. 11.3%) and two-year COST (adjusted R ® ϭ 15.7% vs. 13.9%), adjusting for age and sex. The updated CCI was a better predictor of one-and two-year HOS (AIC ϭ 8581, 13821) as well as one-and two-year ED (AIC ϭ 17009, 25200). In the logistic regression models, the updated CCI performed better in predicting all study outcomes (c ϭ 0.619 to 0.754) than the original CCI (c ϭ 0.611 to 0.737). CONCLUSIONS: In a population of diabetic patients, the updated CCI showed improved predictive performance compared to the original CCI. The updated CCI should be validated in other patient populations. . Dementia patients were identified using cccodex and International Classification of Diseases, 9 th Revision, Clinical Modification (ICD-9CM) codes. Total health care expenditure was defined as the sum of inpatient, outpatient and pharmacy costs. The comorbidity measures evaluated were diagnosis based scales (identified using ICD-9CM codes): D'Hoore's adaptation of Charlson comorbidity index (CCI), and Elixhauser comorbidity algorithm; and prescription based scales (identified using national drug codes): Chronic Disease Score (CDS-1 and CDS-2). The performance of comorbidity measures was compared using the adjusted R® derived from multiple linear regression models that included baseline demographic (age, race, sex) socio-economic (income, insurance, geographic region), and perceived health status variables. The performance of combined diagnoses and prescription-based scores was also compared. RESULTS: The adjusted R 2 of the baseline model was 0.1464. Model performance after the addition of comorbidity measures was: Elixhauser (0.3326), CDS-2 (0.3427), Charlson/D'Hoore (0.2184), and CDS-1 (0.2388). The performance of combined diagnosis and prescription based measures was: CDS-2/Elixhauser (0.4356), CDS 1/Elixhauser (0.3979), CDS-2/D'Hoore (0.3493) and CDS-1/D'Hoore (0.2573). CONCLUSIONS: The Elixhauser and CDS-2 comorbidity measures combined had the highest prediction of health care expenditure in patients with dementia. The improvement in risk adjustment from the combination of diagnosis and prescription based measures indicates that these different types of measures may be capturing different aspects of the construct of comorbidity, constructs other than comorbidity, or both.
EE3
PERFORMANCE OF DIFFERENT COMORBIDITY MEASURES IN PREDICTING HEALTH CARE EXPENDITURE IN PATIENTS WITH DEMENTIA
EE4 BOOTSTRAPPING USED TO PROVIDE ROBUST MEAN AND VARIANCE ESTIMATES FOR COMPARING PATIENTS TREATED WITH LIRAGLUTIDE TO A LARGE COMPARISON COHORT
McAdam Marx C 1 , Ye X 1 , Bouchard J 2 , Aagren M 2 , Conner C 3 , Brixner D 1 1 University of Utah, Salt Lake City, UT, USA, 2 Novo Nordisk, Inc., Princeton, NJ, USA, 3 Novo Nordisk, Inc., Redmond, WA, USA OBJECTIVES: In an analyses of patients with type 2 diabetes (T2DM) in a large electronic medical record (EMR) database, small differences were found to be statistically significant between Nϭ1162 patients with liraglutide versus a comparison cohort due to the comparison group sample size (nϭ274,922). The purpose of this study is to evaluate a bootstrapping technique to provide robust mean and variance estimates for comparison patients, thereby helping to address the issue of being over-powered. METHODS: Study patients were age Ն18 years with T2DM, prescribed liraglutide or other antidiabetic drug January 1, 2010 to July 16, 2010 and with Ն13 months of EMR activity. Bootstrapping was used to provide cohort mean, standard deviation, and 95% CI estimates for the comparison cohort and were calculated as the mean of the mean values identified in 1000 random draws with replacement of 1162 comparison patients. Means (95% CI) were compared for continuous variables (age, HbA1c and blood pressure [BP]) for liraglutide versus the overall comparison group and to bootstrap estimates. RESULTS: Of 1162 liraglutide patients, mean (95% CI) age was 55.5 (54.9, 56.2) years versus 60.9 (60.8, 60.9) years for all comparison patients and 60.9 (60.1, 61.6) years for comparison patients per bootstrap estimates (both pϽ0.05). HbA1c was 8.12% (8.00, 8.24) for liraglutide versus 7.62% (7.61, 7.63) and 7.63% (7.49, 7.76) for all comparison patients and per bootstrap, respectively (both pϽ0.05). BP was 127.0 (126.1, 127.8)/75.8 (75.3, 76.4) A9
